SlideShare a Scribd company logo
Regulation: when less is more

Counterfactual

www.clivebates.com
@clive_bates
WHO – 1 billion deaths
I smoked for 45 years and tried every NRT
product available, none of them worked. I
continued to smoke even though my health was
getting worse, resulting in COPD and using
oxygen daily.
September 2011 I discovered e-cigarettes and
they worked. It was like someone handed me a
miracle. In less than a week I stopped using
regular cigarettes. I haven’t had a tobacco
cigarette since.

Unsolicited comment left on www.clivebates.com
From WHO Tobacco Atlas 2006 edition
The Endgame?
Billion adults > 15 years

Projected global adult population growth
9.0
8.0

Adult
population

7.0
6.0

5.0
4.0
3.0
2.0
1.0

0.0
2010

2015

2020

2025

2030

2035

Smokers: WHO Tobacco Atlas 2006. Population: UN

2040

2045

2050
The Endgame?
Billion adults > 15 years

Projected global adult population growth
9.0
8.0

Adult
population

7.0
6.0

5.0
4.0
3.0

Smoker
population at
constant
prevalence

2.0
1.0

0.0
2010

2015

2020

2025

2030

2035

Smokers: WHO Tobacco Atlas 2006. Population: UN

2040

2045

2050
The endgame?
Billion adults > 15 years

Scenarios for future smoker population
2.5
Constant
prevalence
(28%)

2.0

1.5

1.0

0.5

0.0
2010

2015

2020

2025

2030

Scenario – 15% global prevalence by 2050

2035

2040

2045

2050
The endgame?
Billion adults > 15 years

Scenarios for future smoker population
2.5
Constant
prevalence
(28%)

2.0

1.5
Global smoking
prevalence
declines to 15%
1.0

0.5

0.0
2010

2015

2020

2025

2030

Scenario – 15% global prevalence by 2050

2035

2040

2045

2050
If all goes well
Billion adults > 15 years

Scenarios for future smoker population
2.5
Constant
prevalence
(28%)

2.0

Contested by tobacco control

1.5

Global smoking
prevalence
declines to 15%
1.0

HARM

0.5

0.0
2010

2015

2020

2025

2030

2035

2040

2045

2050
The endgame – a nicotine product contest?
Billion adults > 15 years

Scenarios for future nicotine markets
2.5
Constant
prevalence
(28%)

2.0

Contested by tobacco control

1.5

Global nicotine
prevalence
declines to 15%
1.0

Contested by nicotine products
0.5

0.0
2010

2015

2020

2025

2030

2035

2040

2045

2050
How far could low-risk nicotine products go?
Billion adults > 15 years

Scenarios for future nicotine markets
2.5
Constant
prevalence
(28%)

2.0

Contested by tobacco control

1.5

Global nicotine
prevalence
declines to 15%
1.0

Contested by low risk nicotine products

Global smoking
prevalence
declines to 5%

0.5

Cigarettes and other combustible tobacco
0.0
2010

2015

2020

2025

2030

2035

2040

2045

2050
How far could low-risk nicotine products go?
Billion adults > 15 years

Scenarios for future nicotine markets
2.5

2.0

1.5

1.0

This boundary matters most for public health

0.5

0.0
2010

2015

2020

2025

2030

2035

2040

2045

2050
The endgame: analyst view

Consumption of e-cigs may overtake traditional
cigarettes in the next decade … and they’ll only
evolve and improve as time goes forward.
Bonnie Herzog, Wells Fargo Securities, 2013
The endgame: analyst view

Consumption of e-cigs may overtake traditional
cigarettes in the next decade … and they’ll only
evolve and improve as time goes forward.
Bonnie Herzog, Wells Fargo Securities, 2013
50:50 by 2030
Billion adults > 15 years

”Modified Herzog scenario" for future nicotine markets
2.5
Constant
prevalence
(28%)

2.0

1.5
Global nicotine
prevalence
declines to 15%
1.0

"E-cigarettes overtake
cigarettes by 2030"

0.5

0.0
2010

Global smoking
prevalence
declines to 5%

2015

2020

2025

2030

2035

2040

2045

2050
Who is this?

Mitch Zeller
(now) Director of the Center for Tobacco Products
FDA
Harm reduction equation

Harm reduction = Reduced risk x Number who switch

Product toxicity &
other risks

Product attractiveness

Consumer preference
Harm reduction equation

Harm reduction = Reduced risk x Number who switch

Product toxicity &
other risks

Product attractiveness

Consumer preference
Harm reduction categories – risk estimates

Crude estimate of risk – Cigs = 100

120

100
80
60
40
20
0
Cigarettes

Heat not burn

Smokeless

E-cigs

NRT
Focus on the right relative risk
More regulation
Lower risk
regulated e-cig

0

10

0
e-cigarettes

“unregulated” e-cig

10
0

100
cigarette
Harm reduction equation

Harm reduction = Reduced risk x Number who switch

Product toxicity &
other risks

Product attractiveness

Consumer preference
Analysts
We remain very bullish on the vast potential of e-cigs given the
rapid pace of innovation. [We believe] that the benefits of e-cigs
are becoming increasingly apparent to consumers, helping to
drive trial and repeat purchases aided by stepped-up advertising
and a lot of internet “buzz”
Wells Fargo
Regulation comes at a price

Fewer, duller
innovations

Less
personalisation

Slower
innovation
pace

Trusted brands
& firms
destroyed

Greatly
reduced variety
& niche
products

Increased cost

Boring
branding &
marketing

Oligopoly &
reduced
competition

Reduced
appeal

Black market,
DIY
Harm reduction equation

Harm reduction = Reduced risk x Number who switch

Trade offs
Conclusion 1. The perfectly risk free product that no-one
wants scores badly in the harm reduction equation

Conclusion 2. A diverse range of products with substantially
reduced risk lets each smoker decide which product is best
Triple negative

Tough on harm reduction
Specialised medicines language
Consistent drug dosing

Adverse drug reactions

Safety

Quality

Treats or prevents disease

Efficacy
Getting tough on harm reduction?
Counter-productive

Harm reducing

Safety

Safest possible

Safe enough

Quality

Control processes (eg. GMP)

Proportionate standards

Efficacy

Regulator decides

Consumer decides

Labelling

Warns of danger

Encourages switching

Marketing

Like medicines

Like consumer products

Bans on use

Fear of ‘renormalisation’

Normalise harm reduction

Retail

Pharmacies / as tobacco

General sales

Age restrictions

Adults

Makes little real difference

Taxation

Like tobacco

Fiscal incentive to switch
What do analysts think…?
We believe many current suppliers would struggle to meet
medical standards, and for the UK they may have to by 2016. Big
players with deeper pockets would survive and prices could rise
– a hugely preferable outcome for Tobacco.
BNP Paribas
Tougher regulation, as well as providing a relative advantage to
their e-cigarette divisions, would result in higher prices for ecigarettes – which could also benefit tobacco companies by
limiting their attraction for smokers and slowing the decline in
tobacco sales.
Fitch
What do analysts think…?
We believe many current suppliers would struggle to meet
medical standards, and for the UK they may have to by 2016. Big
players with deeper pockets would survive and prices could rise
– a hugely preferable outcome for Tobacco.
BNP Paribas
Tougher regulation, as well as providing a relative advantage to
their e-cigarette divisions, would result in higher prices for ecigarettes – which could also benefit tobacco companies by
limiting their attraction for smokers and slowing the decline in
tobacco sales.
Fitch
European Parliament – amendment 170
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Requires medicines regulation if claim made
Requires Article 17 notification regime otherwise
Emphasises general safety requirement
Applies Article 16 – cross border distance sales
Applies advertising directive 2003/33/EC and audiovisual services 2010/13/EU
Information leaflet
Warning “this product is intended for use by existing smokers. It contains
nicotine which is a highly addictive substance”
Warning size - 30% or 40% (Council =30%) and specification from Article 10
30mg/ml threshold – “are not placed on the market” (?medicine)
Age restriction (no less than 18)
Restriction on additives – application of Article 6.4 (vitamins etc)
No tobacco branding
Allows flavourings
Requires sales allowed ‘outside pharmacies’
Review
Purpose built regulation for e-cigs / NCPs
1.

Accountabilities – responsible person

2.

Disclosure and notification regime

3.

Labeling and consumer information

4.

Safety assessment and product file

5.

Contaminants / purity

6.

Prohibited ingredients

7.

Specific standards for vaping devices CEN/ISO

8.

Updating: review & technical committee

9.

Marketing (like alcohol?) – mostly member state

10. Retail sales age restriction – member states
11. … public vaping?
Harm reduction equation with population effects

Harm reduction = Reduced risk x Number who switch
- Extra smokers + Extra quitters

Gateway to smoking
Dual use
Reduced quitting
Normalising smoking

Gateway exits
Complete cessation
Extra quitting
Normalising non-smoking
Conclusion
• Be positive about the (vast) potential
• Put the (minor) risks in perspective
• Regulate as though the 1 billion matter most
Thank you…
Counterfactual

www.clivebates.com
@clive_bates

More Related Content

Similar to E-Cigarette Summit Speaker: Clive Bates

Electronic Cigarette Regulations: When Less is More
Electronic Cigarette Regulations: When Less is MoreElectronic Cigarette Regulations: When Less is More
Electronic Cigarette Regulations: When Less is More
ecigarettesummit
 
Wells Fargo 2013
Wells Fargo 2013 Wells Fargo 2013
Wells Fargo 2013
Clive Bates
 
Global Forum on Nicotine 2016: What would good regulation look like
Global Forum on Nicotine 2016: What would good regulation look likeGlobal Forum on Nicotine 2016: What would good regulation look like
Global Forum on Nicotine 2016: What would good regulation look like
Clive Bates
 
The APPH Standard: What Does it Actually Mean?
The APPH Standard:  What Does it Actually Mean?The APPH Standard:  What Does it Actually Mean?
The APPH Standard: What Does it Actually Mean?
Clive Bates
 
hongkong_presentation
hongkong_presentationhongkong_presentation
hongkong_presentation
Burning Brain Society
 
Smoking
SmokingSmoking
Smoking
eman fathi
 
The tobacco products directive: an opportunity for a generation
The tobacco products directive: an opportunity for a generationThe tobacco products directive: an opportunity for a generation
The tobacco products directive: an opportunity for a generation
European Economic and Social Committee - SOC Section
 
MPOWER Package
MPOWER PackageMPOWER Package
MPOWER Package
Smoke-Free Albay Network
 
Competent or careless? Directions in European policy on low-risk nicotine pr...
Competent or careless?  Directions in European policy on low-risk nicotine pr...Competent or careless?  Directions in European policy on low-risk nicotine pr...
Competent or careless? Directions in European policy on low-risk nicotine pr...
Clive Bates
 
How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...
How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...
How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...
Lindsay Fox
 
Dr. jean francois etter the royal society 11-13
Dr. jean francois etter the royal society 11-13Dr. jean francois etter the royal society 11-13
Dr. jean francois etter the royal society 11-13
Brownstone Communications LLC
 
GASO 11.20.2014 - The Tobacco Epidemic in the 21st Century
GASO 11.20.2014 - The Tobacco Epidemic in the 21st CenturyGASO 11.20.2014 - The Tobacco Epidemic in the 21st Century
GASO 11.20.2014 - The Tobacco Epidemic in the 21st Century
Georgia State School of Public Health
 
Deborah Arnott - E-Cigarette Summit 2014
Deborah Arnott - E-Cigarette Summit 2014Deborah Arnott - E-Cigarette Summit 2014
Deborah Arnott - E-Cigarette Summit 2014
Neil Mclaren
 
BAT presentation - Team 2
BAT presentation - Team 2BAT presentation - Team 2
BAT presentation - Team 2
João Simões
 
Ash 897
Ash 897Ash 897
Fda Presentation
Fda PresentationFda Presentation
E-Cigarettes - how should Public Health respond - Martin Dockrell
E-Cigarettes - how should Public Health respond - Martin DockrellE-Cigarettes - how should Public Health respond - Martin Dockrell
E-Cigarettes - how should Public Health respond - Martin Dockrell
Institute of Public Health in Ireland
 
Smoking and lung cancer and now Covid
Smoking and lung cancer and now CovidSmoking and lung cancer and now Covid
Smoking and lung cancer and now Covid
Robert J Miller MD
 
US E-cigarette Summit: Taming the nicotine industrial complex
US E-cigarette Summit: Taming the nicotine industrial complexUS E-cigarette Summit: Taming the nicotine industrial complex
US E-cigarette Summit: Taming the nicotine industrial complex
Clive Bates
 
The end of what? UK E-cigarette Summit 2023
The end of what? UK E-cigarette Summit 2023The end of what? UK E-cigarette Summit 2023
The end of what? UK E-cigarette Summit 2023
Clive Bates
 

Similar to E-Cigarette Summit Speaker: Clive Bates (20)

Electronic Cigarette Regulations: When Less is More
Electronic Cigarette Regulations: When Less is MoreElectronic Cigarette Regulations: When Less is More
Electronic Cigarette Regulations: When Less is More
 
Wells Fargo 2013
Wells Fargo 2013 Wells Fargo 2013
Wells Fargo 2013
 
Global Forum on Nicotine 2016: What would good regulation look like
Global Forum on Nicotine 2016: What would good regulation look likeGlobal Forum on Nicotine 2016: What would good regulation look like
Global Forum on Nicotine 2016: What would good regulation look like
 
The APPH Standard: What Does it Actually Mean?
The APPH Standard:  What Does it Actually Mean?The APPH Standard:  What Does it Actually Mean?
The APPH Standard: What Does it Actually Mean?
 
hongkong_presentation
hongkong_presentationhongkong_presentation
hongkong_presentation
 
Smoking
SmokingSmoking
Smoking
 
The tobacco products directive: an opportunity for a generation
The tobacco products directive: an opportunity for a generationThe tobacco products directive: an opportunity for a generation
The tobacco products directive: an opportunity for a generation
 
MPOWER Package
MPOWER PackageMPOWER Package
MPOWER Package
 
Competent or careless? Directions in European policy on low-risk nicotine pr...
Competent or careless?  Directions in European policy on low-risk nicotine pr...Competent or careless?  Directions in European policy on low-risk nicotine pr...
Competent or careless? Directions in European policy on low-risk nicotine pr...
 
How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...
How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...
How E-Cigarettes Should be Regulated - Professor Jean-François ETTER - E-Ciga...
 
Dr. jean francois etter the royal society 11-13
Dr. jean francois etter the royal society 11-13Dr. jean francois etter the royal society 11-13
Dr. jean francois etter the royal society 11-13
 
GASO 11.20.2014 - The Tobacco Epidemic in the 21st Century
GASO 11.20.2014 - The Tobacco Epidemic in the 21st CenturyGASO 11.20.2014 - The Tobacco Epidemic in the 21st Century
GASO 11.20.2014 - The Tobacco Epidemic in the 21st Century
 
Deborah Arnott - E-Cigarette Summit 2014
Deborah Arnott - E-Cigarette Summit 2014Deborah Arnott - E-Cigarette Summit 2014
Deborah Arnott - E-Cigarette Summit 2014
 
BAT presentation - Team 2
BAT presentation - Team 2BAT presentation - Team 2
BAT presentation - Team 2
 
Ash 897
Ash 897Ash 897
Ash 897
 
Fda Presentation
Fda PresentationFda Presentation
Fda Presentation
 
E-Cigarettes - how should Public Health respond - Martin Dockrell
E-Cigarettes - how should Public Health respond - Martin DockrellE-Cigarettes - how should Public Health respond - Martin Dockrell
E-Cigarettes - how should Public Health respond - Martin Dockrell
 
Smoking and lung cancer and now Covid
Smoking and lung cancer and now CovidSmoking and lung cancer and now Covid
Smoking and lung cancer and now Covid
 
US E-cigarette Summit: Taming the nicotine industrial complex
US E-cigarette Summit: Taming the nicotine industrial complexUS E-cigarette Summit: Taming the nicotine industrial complex
US E-cigarette Summit: Taming the nicotine industrial complex
 
The end of what? UK E-cigarette Summit 2023
The end of what? UK E-cigarette Summit 2023The end of what? UK E-cigarette Summit 2023
The end of what? UK E-cigarette Summit 2023
 

Recently uploaded

CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
MGM SCHOOL/COLLEGE OF NURSING
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Donc Test
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
BrissaOrtiz3
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
Swastik Ayurveda
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
chandankumarsmartiso
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
Swastik Ayurveda
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 

Recently uploaded (20)

CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 

E-Cigarette Summit Speaker: Clive Bates

  • 1. Regulation: when less is more Counterfactual www.clivebates.com @clive_bates
  • 2. WHO – 1 billion deaths
  • 3.
  • 4. I smoked for 45 years and tried every NRT product available, none of them worked. I continued to smoke even though my health was getting worse, resulting in COPD and using oxygen daily. September 2011 I discovered e-cigarettes and they worked. It was like someone handed me a miracle. In less than a week I stopped using regular cigarettes. I haven’t had a tobacco cigarette since. Unsolicited comment left on www.clivebates.com
  • 5. From WHO Tobacco Atlas 2006 edition
  • 6. The Endgame? Billion adults > 15 years Projected global adult population growth 9.0 8.0 Adult population 7.0 6.0 5.0 4.0 3.0 2.0 1.0 0.0 2010 2015 2020 2025 2030 2035 Smokers: WHO Tobacco Atlas 2006. Population: UN 2040 2045 2050
  • 7. The Endgame? Billion adults > 15 years Projected global adult population growth 9.0 8.0 Adult population 7.0 6.0 5.0 4.0 3.0 Smoker population at constant prevalence 2.0 1.0 0.0 2010 2015 2020 2025 2030 2035 Smokers: WHO Tobacco Atlas 2006. Population: UN 2040 2045 2050
  • 8. The endgame? Billion adults > 15 years Scenarios for future smoker population 2.5 Constant prevalence (28%) 2.0 1.5 1.0 0.5 0.0 2010 2015 2020 2025 2030 Scenario – 15% global prevalence by 2050 2035 2040 2045 2050
  • 9. The endgame? Billion adults > 15 years Scenarios for future smoker population 2.5 Constant prevalence (28%) 2.0 1.5 Global smoking prevalence declines to 15% 1.0 0.5 0.0 2010 2015 2020 2025 2030 Scenario – 15% global prevalence by 2050 2035 2040 2045 2050
  • 10. If all goes well Billion adults > 15 years Scenarios for future smoker population 2.5 Constant prevalence (28%) 2.0 Contested by tobacco control 1.5 Global smoking prevalence declines to 15% 1.0 HARM 0.5 0.0 2010 2015 2020 2025 2030 2035 2040 2045 2050
  • 11. The endgame – a nicotine product contest? Billion adults > 15 years Scenarios for future nicotine markets 2.5 Constant prevalence (28%) 2.0 Contested by tobacco control 1.5 Global nicotine prevalence declines to 15% 1.0 Contested by nicotine products 0.5 0.0 2010 2015 2020 2025 2030 2035 2040 2045 2050
  • 12. How far could low-risk nicotine products go? Billion adults > 15 years Scenarios for future nicotine markets 2.5 Constant prevalence (28%) 2.0 Contested by tobacco control 1.5 Global nicotine prevalence declines to 15% 1.0 Contested by low risk nicotine products Global smoking prevalence declines to 5% 0.5 Cigarettes and other combustible tobacco 0.0 2010 2015 2020 2025 2030 2035 2040 2045 2050
  • 13. How far could low-risk nicotine products go? Billion adults > 15 years Scenarios for future nicotine markets 2.5 2.0 1.5 1.0 This boundary matters most for public health 0.5 0.0 2010 2015 2020 2025 2030 2035 2040 2045 2050
  • 14. The endgame: analyst view Consumption of e-cigs may overtake traditional cigarettes in the next decade … and they’ll only evolve and improve as time goes forward. Bonnie Herzog, Wells Fargo Securities, 2013
  • 15. The endgame: analyst view Consumption of e-cigs may overtake traditional cigarettes in the next decade … and they’ll only evolve and improve as time goes forward. Bonnie Herzog, Wells Fargo Securities, 2013
  • 16. 50:50 by 2030 Billion adults > 15 years ”Modified Herzog scenario" for future nicotine markets 2.5 Constant prevalence (28%) 2.0 1.5 Global nicotine prevalence declines to 15% 1.0 "E-cigarettes overtake cigarettes by 2030" 0.5 0.0 2010 Global smoking prevalence declines to 5% 2015 2020 2025 2030 2035 2040 2045 2050
  • 17. Who is this? Mitch Zeller (now) Director of the Center for Tobacco Products FDA
  • 18. Harm reduction equation Harm reduction = Reduced risk x Number who switch Product toxicity & other risks Product attractiveness Consumer preference
  • 19. Harm reduction equation Harm reduction = Reduced risk x Number who switch Product toxicity & other risks Product attractiveness Consumer preference
  • 20. Harm reduction categories – risk estimates Crude estimate of risk – Cigs = 100 120 100 80 60 40 20 0 Cigarettes Heat not burn Smokeless E-cigs NRT
  • 21. Focus on the right relative risk More regulation Lower risk regulated e-cig 0 10 0 e-cigarettes “unregulated” e-cig 10 0 100 cigarette
  • 22. Harm reduction equation Harm reduction = Reduced risk x Number who switch Product toxicity & other risks Product attractiveness Consumer preference
  • 23. Analysts We remain very bullish on the vast potential of e-cigs given the rapid pace of innovation. [We believe] that the benefits of e-cigs are becoming increasingly apparent to consumers, helping to drive trial and repeat purchases aided by stepped-up advertising and a lot of internet “buzz” Wells Fargo
  • 24. Regulation comes at a price Fewer, duller innovations Less personalisation Slower innovation pace Trusted brands & firms destroyed Greatly reduced variety & niche products Increased cost Boring branding & marketing Oligopoly & reduced competition Reduced appeal Black market, DIY
  • 25. Harm reduction equation Harm reduction = Reduced risk x Number who switch Trade offs Conclusion 1. The perfectly risk free product that no-one wants scores badly in the harm reduction equation Conclusion 2. A diverse range of products with substantially reduced risk lets each smoker decide which product is best
  • 26.
  • 27. Triple negative Tough on harm reduction
  • 28. Specialised medicines language Consistent drug dosing Adverse drug reactions Safety Quality Treats or prevents disease Efficacy
  • 29. Getting tough on harm reduction? Counter-productive Harm reducing Safety Safest possible Safe enough Quality Control processes (eg. GMP) Proportionate standards Efficacy Regulator decides Consumer decides Labelling Warns of danger Encourages switching Marketing Like medicines Like consumer products Bans on use Fear of ‘renormalisation’ Normalise harm reduction Retail Pharmacies / as tobacco General sales Age restrictions Adults Makes little real difference Taxation Like tobacco Fiscal incentive to switch
  • 30. What do analysts think…? We believe many current suppliers would struggle to meet medical standards, and for the UK they may have to by 2016. Big players with deeper pockets would survive and prices could rise – a hugely preferable outcome for Tobacco. BNP Paribas Tougher regulation, as well as providing a relative advantage to their e-cigarette divisions, would result in higher prices for ecigarettes – which could also benefit tobacco companies by limiting their attraction for smokers and slowing the decline in tobacco sales. Fitch
  • 31. What do analysts think…? We believe many current suppliers would struggle to meet medical standards, and for the UK they may have to by 2016. Big players with deeper pockets would survive and prices could rise – a hugely preferable outcome for Tobacco. BNP Paribas Tougher regulation, as well as providing a relative advantage to their e-cigarette divisions, would result in higher prices for ecigarettes – which could also benefit tobacco companies by limiting their attraction for smokers and slowing the decline in tobacco sales. Fitch
  • 32. European Parliament – amendment 170 • • • • • • • • • • • • • • • Requires medicines regulation if claim made Requires Article 17 notification regime otherwise Emphasises general safety requirement Applies Article 16 – cross border distance sales Applies advertising directive 2003/33/EC and audiovisual services 2010/13/EU Information leaflet Warning “this product is intended for use by existing smokers. It contains nicotine which is a highly addictive substance” Warning size - 30% or 40% (Council =30%) and specification from Article 10 30mg/ml threshold – “are not placed on the market” (?medicine) Age restriction (no less than 18) Restriction on additives – application of Article 6.4 (vitamins etc) No tobacco branding Allows flavourings Requires sales allowed ‘outside pharmacies’ Review
  • 33.
  • 34.
  • 35. Purpose built regulation for e-cigs / NCPs 1. Accountabilities – responsible person 2. Disclosure and notification regime 3. Labeling and consumer information 4. Safety assessment and product file 5. Contaminants / purity 6. Prohibited ingredients 7. Specific standards for vaping devices CEN/ISO 8. Updating: review & technical committee 9. Marketing (like alcohol?) – mostly member state 10. Retail sales age restriction – member states 11. … public vaping?
  • 36. Harm reduction equation with population effects Harm reduction = Reduced risk x Number who switch - Extra smokers + Extra quitters Gateway to smoking Dual use Reduced quitting Normalising smoking Gateway exits Complete cessation Extra quitting Normalising non-smoking
  • 37. Conclusion • Be positive about the (vast) potential • Put the (minor) risks in perspective • Regulate as though the 1 billion matter most